$5.97-0.68 (-10.23%)
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States.
Aspire Biopharma Holdings, Inc. in the Healthcare sector is trading at $5.97. The stock is currently near its 52-week low of $0.11, remaining 6.3% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 35/100 signals elevated caution as multiple indicators diverge.
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers sublingual aspirin product that is a soluble, PH neutral, a...
Aspire Biopharma Holdings (NASDAQ:ASBP) is one of the worst performing NASDAQ stocks so far in 2026. On April 27, Aspire Biopharma authorized a $5 million share repurchase program using existing cash. The board initiated the buyback due to confidence in the company’s financial strength, its drug development pipeline, and the potential value of its pending […]
Aspire Biopharma (ASBP) wholly owned subsidiary, Buzz Bomb Caffeine Company, announced a strategic brand management and distribution agreement with Blue Shark Beverages. Effective February 1, the relationship is expected to drive the retail expansion of BUZZ BOMB, a proprietary 50mg sublingual caffeine stick pack in four flavors, across key Southern California markets. The rollout will debut in Palm Springs and surrounding cities in the Coachella Valley, followed by a phased expansion into the L
Aspire Biopharma (ASBP) announced the filing of a new provisional patent application with the United States Patent and Trademark Office. The application, titled “A Sublingual Powder Formulation of Clopidogrel and Methods of Use Thereof,” covers the first-ever sublingual formulation of clopidogrel, the active pharmaceutical ingredient in the widely prescribed blood thinner Plavix. This development represents a series of sublingual-based therapeutic alternatives the Company intends to commercializ
Nu Holdings Ltd. 35,303,567 16.69
Aspire Biopharma Holdings Inc. (NASDAQ:ASBP) is one of the best penny stocks under $1 to buy now. On July 9, Aspire Biopharma Holdings announced positive initial consumer feedback for its new sublingual pre-workout supplement, called BUZZ BOMB. The product features 50mg of caffeine and provides sustained energy and mental focus to athletes and fitness enthusiasts, […]